Phase III trial of pramlintide + metreleptin combination therapy in patients with obesity.

Trial Profile

Phase III trial of pramlintide + metreleptin combination therapy in patients with obesity.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2011

At a glance

  • Drugs Metreleptin (Primary) ; Pramlintide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Amylin Pharmaceuticals; Takeda
  • Most Recent Events

    • 04 Aug 2011 Status changed from planning to discontinued.
    • 24 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top